Symptomatic and Promising Disease-Modifying Treatments for Dementia Syndromes
Abstract
Dementia could be defined as a range of cognitive and behavioral symptoms, including memory loss, executive dysfunction, and change in personality, and a reduction in a person's ability to carry out daily activities. The most common types of dementia are Alzheimer's disease (AD), vascular dementia, mixed dementia, dementia with Lewy bodies, and frontotemporal dementia (1).
All currently approved treatments for dementia are symptomatic treatments that could influence cognitive and behavioral symptoms without changing the underlying neuropathological progression of the disease (2).
1. Chertkow H, Feldman HH, Jacova C, Massoud F. Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther. 2013;5(Suppl 1):S2.
2. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867-73.
3. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr. 2002;14:93-126.
4. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005(2):Cd003154.
5. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408-14.
6. Esang M, Gupta M. Aducanumab as a Novel Treatment for Alzheimer's disease: A Decade of Hope, Controversies, and the Future. Cureus. 2021;13(8):e17591.
7. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (NY). 2018;4:195-214.
8. Andrews M, Tousi B, Sabbagh MN. 5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress. Neurol Ther. 2018;7(1):51-8.
9. Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. Alzheimers Res Ther. 2021;13(1):62.
10. Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Mol Neurodegener. 2021;16(1):2.
11. Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Molecular Neurodegeneration. 2021;16(1):2.
12. Schenk D, Basi GS, Pangalos MN. Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med. 2012;2(9):a006387.
13. Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):18.
14. Hampel H, Caraci F, Cuello AC, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer's disease. Front Immunol. 2020;11:456.
15. Cordero JG, García-Escudero R, Avila J, Gargini R, García-Escudero V. Benefit of Oleuropein Aglycone for Alzheimer's Disease by Promoting Autophagy. Oxid Med Cell Longev. 2018;2018:5010741.
16. Shi M, Chu F, Zhu F, Zhu J. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab. Front Aging Neurosci. 2022;14:870517.
17. Silvestro S, Valeri A, Mazzon E. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis? International Journal of Molecular Sciences. 2022;23(4):2011.
18. Cummings J, Lee G, Nahed P, Kambar M, Zhong K, Fonseca J, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (NY). 2022;8(1):e12295.
19. Cruz MP. Pimavanserin (Nuplazid): A treatment for hallucinations and delusions associated with Parkinson’s disease. PT. 2017;42(6):368-71.
2. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867-73.
3. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr. 2002;14:93-126.
4. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005(2):Cd003154.
5. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408-14.
6. Esang M, Gupta M. Aducanumab as a Novel Treatment for Alzheimer's disease: A Decade of Hope, Controversies, and the Future. Cureus. 2021;13(8):e17591.
7. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (NY). 2018;4:195-214.
8. Andrews M, Tousi B, Sabbagh MN. 5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress. Neurol Ther. 2018;7(1):51-8.
9. Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. Alzheimers Res Ther. 2021;13(1):62.
10. Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Mol Neurodegener. 2021;16(1):2.
11. Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Molecular Neurodegeneration. 2021;16(1):2.
12. Schenk D, Basi GS, Pangalos MN. Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med. 2012;2(9):a006387.
13. Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):18.
14. Hampel H, Caraci F, Cuello AC, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer's disease. Front Immunol. 2020;11:456.
15. Cordero JG, García-Escudero R, Avila J, Gargini R, García-Escudero V. Benefit of Oleuropein Aglycone for Alzheimer's Disease by Promoting Autophagy. Oxid Med Cell Longev. 2018;2018:5010741.
16. Shi M, Chu F, Zhu F, Zhu J. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab. Front Aging Neurosci. 2022;14:870517.
17. Silvestro S, Valeri A, Mazzon E. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis? International Journal of Molecular Sciences. 2022;23(4):2011.
18. Cummings J, Lee G, Nahed P, Kambar M, Zhong K, Fonseca J, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (NY). 2022;8(1):e12295.
19. Cruz MP. Pimavanserin (Nuplazid): A treatment for hallucinations and delusions associated with Parkinson’s disease. PT. 2017;42(6):368-71.
| Files | ||
| Issue | Vol 10, No 3 (Summer 2022) | |
| Section | Editorial | |
| DOI | https://doi.org/10.18502/jpc.v10i3.10788 | |
| Keywords | ||
| Dementia Alzheimers' disease | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Mohammadian F, Mohebbi N. Symptomatic and Promising Disease-Modifying Treatments for Dementia Syndromes. J Pharm Care. 2022;10(3):94-96.
